Clinical Trial Results:
A phase II, controlled, single centre, open study to evaluate the safety, reactogenicity and immunogenicity of a second vaccination with the low dose influenza vaccine adjuvanted with a reduced dose of AS03, compared to a second dose of Fluarix™ (GlaxoSmithKline Biologicals) administered intramuscularly in subjects 18-60 years previously vaccinated in FLU-LD-004 clinical trial.
Due to the EudraCT – Results system being out of service between 31 July 2015 and 12 January 2016, these results have been published in compliance with revised timelines
Summary
|
|
EudraCT number |
2007-002783-10 |
Trial protocol |
BE |
Global completion date |
12 Dec 2007
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
16 Oct 2016
|
First version publication date |
16 Oct 2016
|
Other versions |
|
Summary report(s) |
110674-Clinical-Study-Result-Summary |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.